2020 SARS-CoV-2 Diversification in the United States: Establishing a Pre-vaccination Baseline

Overview

Journal medRxiv

Date 2021 Jun 15

PMID 34127980

Authors

Adam A Capoferri

Wei Shao

Jon Spindler

John M Coffin

Jason W Rausch

Mary F Kearney

Affiliations

Soon will be listed here.

Abstract

One Sentence Summary: SARS-CoV-2 genetic diversity in the U.S. increased 3-fold in 2020 and 54 emergent nonsynonymous mutations were detected.

References

Ladner J, Larsen B, Bowers J, Hepp C, Bolyen E, Folkerts M . An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona. mBio. 2020; 11(5). PMC: 7474171. DOI: 10.1128/mBio.02107-20. View

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

Worobey M, Pekar J, Larsen B, Nelson M, Hill V, Joy J . The emergence of SARS-CoV-2 in Europe and North America. Science. 2020; 370(6516):564-570. PMC: 7810038. DOI: 10.1126/science.abc8169. View

Zhang W, Davis B, Chen S, Sincuir Martinez J, Plummer J, Vail E . Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021; 325(13):1324-1326. PMC: 7879386. DOI: 10.1001/jama.2021.1612. View

Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J . SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021; 29(4):529-539.e3. PMC: 7934674. DOI: 10.1016/j.chom.2021.03.002. View

Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

Dearlove B, Lewitus E, Bai H, Li Y, Reeves D, Joyce M . A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci U S A. 2020; 117(38):23652-23662. PMC: 7519301. DOI: 10.1073/pnas.2008281117. View

Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors J, Coffin J . A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol. 2004; 21(10):1902-12. DOI: 10.1093/molbev/msh196. View

Thomson E, Rosen L, Shepherd J, Spreafico R, da Silva Filipe A, Wojcechowskyj J . Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021; 184(5):1171-1187.e20. PMC: 7843029. DOI: 10.1016/j.cell.2021.01.037. View

10.

Greaney A, Starr T, Gilchuk P, Zost S, Binshtein E, Loes A . Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. 2020; 29(1):44-57.e9. PMC: 7676316. DOI: 10.1016/j.chom.2020.11.007. View

11.

Kemp S, Collier D, Datir R, Ferreira I, Gayed S, Jahun A . SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021; 592(7853):277-282. PMC: 7610568. DOI: 10.1038/s41586-021-03291-y. View

12.

Choi B, Choudhary M, Regan J, Sparks J, Padera R, Qiu X . Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020; 383(23):2291-2293. PMC: 7673303. DOI: 10.1056/NEJMc2031364. View

13.

Plante J, Mitchell B, Plante K, Debbink K, Weaver S, Menachery V . The variant gambit: COVID-19's next move. Cell Host Microbe. 2021; 29(4):508-515. PMC: 7919536. DOI: 10.1016/j.chom.2021.02.020. View

14.

Chang S, Pierson E, Koh P, Gerardin J, Redbird B, Grusky D . Mobility network models of COVID-19 explain inequities and inform reopening. Nature. 2020; 589(7840):82-87. DOI: 10.1038/s41586-020-2923-3. View

15.

Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y . SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021; 29(4):522-528.e2. PMC: 7980135. DOI: 10.1016/j.chom.2021.03.008. View

16.

Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A . Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell. 2020; 184(1):64-75.e11. PMC: 7674007. DOI: 10.1016/j.cell.2020.11.020. View

17.

Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

18.

Gonzalez-Reiche A, Hernandez M, Sullivan M, Ciferri B, Alshammary H, Obla A . Introductions and early spread of SARS-CoV-2 in the New York City area. Science. 2020; 369(6501):297-301. PMC: 7259823. DOI: 10.1126/science.abc1917. View

19.

Avanzato V, Matson M, Seifert S, Pryce R, Williamson B, Anzick S . Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020; 183(7):1901-1912.e9. PMC: 7640888. DOI: 10.1016/j.cell.2020.10.049. View

20.

Edara V, Norwood C, Floyd K, Lai L, Davis-Gardner M, Hudson W . Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021; 29(4):516-521.e3. PMC: 7980225. DOI: 10.1016/j.chom.2021.03.009. View